A surprise move from the Food and Drug Administration means that a recovery for Teva Pharmaceutical Industries just got much more difficult. The generic drugmaker has struggled with a heavy debt burden and falling prices of generic drugs in the U.S. Investor worries intensified after generic rival Mylan announced it had won FDA approval to sell a generic version of Teva’s blockbuster branded drug, Copaxone, which treats multiple sclerosis.

Source: Wall Street Journal October 04, 2017 13:48 UTC